🕵️ PMV Pharmaceuticals, Inc. ($PMVP)
SEC insider & ownership activity, last 12 months · CIK 1699382 · every row links its SEC filing
Over the last 12 months insiders sold $1.5M with no open-market buying against it. Orbimed Advisors LLC sold $1.5M in discretionary trades (Oct). BML Investment Partners, L.P. added 6.7% → 9.9%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 1 seller, $1.5M (1 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 0 | – | 1 | $1.5M | Oct 23, 2025 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Srinivas Akkaraju | 9.9% | 13G | Sep 15, 2026 | filing ↗ | |
| BML Investment Partners, L.P. | 9.9% | 13G | Feb 9, 2026 | filing ↗ | |
| TANG Capital Management, LLC | 8.9% | 13G | Sep 23, 2025 | filing ↗ | |
| Kevin Tang | 8.9% | 13G | Sep 23, 2025 | filing ↗ | |
| Samsara BioCapital, L.P. | 5.0% | 13G | Sep 15, 2026 | filing ↗ | |
| Samsara BioCapital GP, LLC | 5.0% | 13G | Sep 15, 2026 | filing ↗ | |
| Samsara Opportunity Fund, L.P. | 5.0% | 13G | Sep 15, 2026 | filing ↗ | |
| Samsara Opportunity Fund GP, LLC | 5.0% | 13G | Sep 15, 2026 | filing ↗ | |
| TANG Capital Partners, LP | 5.0% | 13G | Sep 23, 2025 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| OrbiMed Private Investments V, LP | $1.5M | Oct 23, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material agreement (1.01) | Aug 31, 2026 | filing ↗ |
| Other events (8.01) | Aug 31, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 31, 2026 | filing ↗ |
| Other events (8.01) | Aug 31, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 31, 2026 | filing ↗ |
| Earnings (2.02) | Aug 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 14, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 4, 2026 | filing ↗ |
| Earnings (2.02) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Earnings (2.02) | Mar 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 6, 2026 | filing ↗ |
| Earnings (2.02) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |